Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

医学 彭布罗利珠单抗 耐受性 内科学 实体瘤疗效评价标准 肿瘤科 头颈部鳞状细胞癌 临床研究阶段 人口 不利影响 头颈部癌 临床试验 外科 癌症 免疫疗法 环境卫生
作者
Tanguy Y. Seiwert,Barbara Burtness,Ranee Mehra,Jared Weiss,Raanan Berger,Joseph P. Eder,Karl Heath,Terrill K. McClanahan,Jared Lunceford,Christine K. Gause,Jonathan D. Cheng,Laura Q.M. Chow
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:17 (7): 956-965 被引量:1562
标识
DOI:10.1016/s1470-2045(16)30066-3
摘要

Summary

Background

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options. We aimed to assess the safety, tolerability, and antitumour activity of pembrolizumab, a humanised anti-programmed death receptor 1 (PD-1) antibody, in patients with PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck.

Methods

This study was an open-label, multicentre, phase 1b trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Patients were eligible for enrolment if they were aged 18 years or older, had a confirmed diagnosis of recurrent or metastatic squamous cell carcinoma of the head and neck, and had any level of PD-L1 expression (ie, at least 1% of tumour cells or stroma that were PD-L1-positive by immunohistochemistry). Patients received pembrolizumab 10 mg/kg intravenously every 2 weeks. Primary outcomes were safety in the per-protocol population and the proportion of patients with centrally reviewed overall response per Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1). Overall response was analysed in the full analysis set, which was defined as all patients who had received at least one dose of pembrolizumab, had measurable disease at baseline, and one post-baseline scan or patients without a post-baseline scan who discontinued therapy because of disease progression or a drug-related adverse event. The study is registered with ClinicalTrials.gov, number NCT01848834 and is ongoing, but no longer enrolling patients.

Findings

Of the 104 patients screened between June 7, 2013, and Oct 3, 2013, 81 (78%) were PD-L1-positive. Of these, 60 patients with PD-L1-positive squamous cell carcinoma of the head and neck were enrolled and treated: 23 (38%) were HPV-positive and 37 (62%) were HPV-negative. Pembrolizumab was well tolerated, with 10 (17%) of 60 patients having grade 3–4 drug-related adverse events, the most common of which were increases in alanine aminotransferase and in aspartate aminotransferase, and hyponatraemia, each occurring in two of 60 patients; one patient developed a grade 3 drug-related rash. 27 (45%) of 60 patients experienced a serious adverse event. There were no drug-related deaths. The proportion of patients with an overall response by central imaging review was 18% (eight of 45 patients; 95% CI 8–32) in all patients and was 25% (four of 16 patients; 7–52) in HPV-positive patients and 14% (four of 29 patients; 4–32) in HPV-negative patients.

Interpretation

Pembrolizumab was well tolerated and demonstrated clinically meaningful antitumour activity in recurrent or metastatic squamous cell carcinoma of the head and neck, supporting further study of pembrolizumab as anticancer therapy for advanced head and neck cancers.

Funding

Merck & Co.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
佳里发布了新的文献求助10
1秒前
酸奶花生完成签到 ,获得积分10
1秒前
CT发布了新的文献求助10
2秒前
NexusExplorer应助11111采纳,获得10
3秒前
123完成签到,获得积分10
3秒前
7秒前
酷波er应助冷艳的姿采纳,获得10
8秒前
8秒前
小蘑菇应助缥缈冷安采纳,获得10
8秒前
ccygpp199发布了新的文献求助10
8秒前
NexusExplorer应助佳里采纳,获得10
9秒前
淡淡的向雁完成签到,获得积分10
9秒前
10秒前
10秒前
Jasper应助LJJ采纳,获得10
12秒前
小啦啦3082发布了新的文献求助10
12秒前
12秒前
13秒前
甜甜的悲完成签到,获得积分20
13秒前
今后应助wbh采纳,获得10
13秒前
14秒前
妖妖灵完成签到,获得积分20
14秒前
加油干发布了新的文献求助10
14秒前
彭于晏应助xuan采纳,获得10
14秒前
甜甜的悲发布了新的文献求助10
15秒前
gwenjing发布了新的文献求助10
16秒前
wsj发布了新的文献求助10
18秒前
18秒前
量子星尘发布了新的文献求助10
18秒前
张金蝶发布了新的文献求助10
18秒前
jinzhen发布了新的文献求助10
18秒前
文献发布了新的文献求助30
19秒前
太牛的GGB完成签到,获得积分20
19秒前
20秒前
穿裤子的云完成签到,获得积分10
21秒前
21秒前
今后应助科研通管家采纳,获得10
23秒前
SciGPT应助科研通管家采纳,获得10
23秒前
SYLH应助科研通管家采纳,获得10
23秒前
科研通AI5应助科研通管家采纳,获得10
23秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173